Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Immunotherapy. Univeristy Hospital Ehrlangen, Ehrlangen, Germany



Survival: 9.3 months
   
Toxicity Grade: 4
   
Treatments: Immunotherapy
   
Drugs:
Country: Germany
   
City/State/Province: Ehrlangen
   
Hospital: Univeristy Hospital Ehrlangen
   
Journal: Link
   
Date: 1/2006

Description:
Patients: This phase III study involved a total of 108 patients with metastatic melanoma. Patients were divided into two groups. Group A had 55 patients and Group B had 53 patients. There were 37 men and 18 women in Group A and the median age was 58. In Group B there were 31 men and 22 women and the median age was 59.

Treatment: Patients in Group A received chemotherapy (dacarbazine). Patients in Group B received immunotherapy (autologous peptide loaded dendritic cell vaccination loaded with MHC Class I and II restricted peptides).

Toxicity: Toxicities for both groups included grade 3-4 lethargy, gastro-intestine and neuropathy cramps.

Results: The median overall survival rate for patients in Group A (chemotherapy) was 11.6 months. The median overall survival rate for patients in Group B (immunotherapy) was 9.3 months. The authors concluded that this type of vaccination could not be demonstrated to be more effective than dacarbazine chemotherapy

Correspondence: Prof. D. Schadendorf

E-mail to a Friend Email Physician More Information